Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, and publicly listed on The Stock Exchange of Hong Kong (ticker:2552).  Hua Medicine’s cornerstone product is dorzagliatin, a global first-in-class glucokinase activator (GKA).

​

While many therapies only address the downstream consequences of dysregulated blood glucose, i.e., elevated blood sugar levels, dorzagliatin’s core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, improving glucose sensitivity from the source and helping restore glucose homeostasis.

​

The drug acts on multiple key organs of glucose metabolism including the islets, intestines and liver, exerting a synergistic effect through multiple targets:

• enhancing glucose-stimulated insulin secretion from pancreatic β-cells,

• promoting GLP-1 release from intestinal L-cells, and

• modulating hepatic glucose output through glycogen regulation.

 

This coordinated, multi-organ profile differentiates dorzagliatin from existing oral antidiabetic therapies and reflects Hua Medicine's focus on controlling the progression, and addressing the root cause, of Type 2 diabetes and its associated complications.  It is the only commercialized T2D medication that has demonstrated drug-free remission after the conclusion of its Phase 3 registration trial – a 65% 52-week drug-free remission rate was observed in one of its Phase 3 registration trial among early-stage T2D diabetic patients.

​

Dorzagliatin has been approved in the mainland China market since September 2022 as HuaTangNing, 华堂宁®, where it has been prescribed to over 500,000 patients. 

 

It has been included in China’s National Reimbursement Drug List since January 1, 2024.  In February 2026 it was approved for registration in Hong Kong under the trade name MYHOMSIS®, 華領片®.

 

Looking ahead, Hua Medicine is developing a second generation GKA as a once-daily oral formulation for international expansion. A Phase 1b multiple-ascending dose trial in the United States is currently ongoing.   In addition, large real world evidence studies on dorzagliatin is ongoing, and research is also being conducted on prevention and remission of Type 2 diabetes and treatment of prediabetic patients.